Financing channel feed – Endpoints News

Financing channel feed

Omid Farokhzad’s biotech insiders SPAC opens the deal window with $200M to play with

4 years ago

Eight bets in, Spain's Ysios officially ties a bow around €216M fund

4 years ago

Tim Lu is ready to take his AI-focused biotech to the next level with first big fundraising round

4 years ago

Hunting a T-cell cure for solid tumors, Rick Klausner’s Lyell steers to Nasdaq — with big dreams and fresh fortunes on the line

4 years ago

Spurred on by Moderna and Pfizer's success, a Belgian biotech has big ambitions for its self-amplifying RNA vaccine play

4 years ago

Blackstone enlists a murderers' row of advisors, including ex-Sanofi CEO Olivier Brandicourt, to steer life sciences biz

4 years ago

Weeks out from an $80M launch, a pain and CNS startup is back with a fresh raise. Can an IPO be far behind?

4 years ago

Bipartisan House bill seeks new $30B ‘BioBonds’ loan program to reinvigorate clinical trials

4 years ago

Months after bursting into the bispecific scene out of nowhere, Janux follows the Merck hype to an IPO

4 years ago

A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto

4 years ago

HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic

4 years ago

Aiming to spur the immune responses that checkpoint inhibitors can't, Swiss biotech Numab earns fresh round of cash

4 years ago

Looking to reshape the metastatic cancer landscape, HiberCell fills the tank with a slate of mid-stage tests queued up

4 years ago

Months after Novartis buyout, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

4 years ago

An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up

4 years ago

Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

4 years ago

Europe's new investment firm says it's on a mission to lift up the continent's 'underexploited' science

4 years ago

Patrick Soon-Shiong's former chief scientist takes cancer company public in $155M reverse merger

4 years ago

A T-cell player with backing from Roche takes next big step for BiTE drugs with 'on-off' switch to avoid toxicity

4 years ago

Insider account of Roivant's SPAC deal — and that $7.3B valuation — reveals a few secrets as Matt Gline positions the company as the new ‘Big Pharma’

4 years ago

Ginkgo nabs $DNA, biotech's most sought after ticker, for free in sweetener from NYSE

5 years ago

Larkspur Health Acquisition files to go public as this year's SPAC flood surges over $14B

5 years ago

Kinase inhibitor specialist Kinnate launches Shanghai subsidiary with $35M to market its programs in China

5 years ago

After going down different drug discovery paths, Genentech vets reunite at Foresite Labs to map the 'protein interactome'

5 years ago

First page Previous page 74 75 767778 79 80 Next page Last page